IMUX
Immunic, Inc. NASDAQ$10.62
Mkt Cap $104.8M
52w Low $5.06
55.4% of range
52w High $15.10
50d MA $11.03
200d MA $8.63
P/E (TTM)
-1.6x
EV/EBITDA
-0.7x
P/B
—
Debt/Equity
-0.1x
ROE
1456.2%
P/FCF
-1.0x
RSI (14)
—
ATR (14)
—
Beta
1.37
50d MA
$11.03
200d MA
$8.63
Avg Volume
421.4K
About
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as w…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.90 | -1.20 | -33.3% | 9.48 | +0.0% | +7.6% | +11.8% | +12.9% | +23.4% | +17.1% | +8.6% | — |
| Nov 13, 2025 | AMC | -0.18 | -0.13 | +27.8% | 7.13 | -0.4% | +9.3% | +2.4% | +6.6% | +0.0% | -3.5% | -13.9% | — |
| Aug 7, 2025 | AMC | -0.18 | -0.20 | -11.1% | 9.02 | +3.1% | -3.3% | -5.9% | -5.5% | -8.1% | +1.6% | -8.3% | — |
| May 15, 2025 | AMC | -0.25 | -0.25 | +0.0% | 9.96 | +0.4% | -3.5% | -3.5% | -2.2% | -7.6% | -7.5% | -17.6% | — |
| Mar 31, 2025 | AMC | -0.22 | -0.25 | -13.6% | 10.90 | +2.8% | -1.8% | +1.8% | -3.7% | -8.7% | -13.5% | -9.2% | — |
| Nov 7, 2024 | AMC | -0.22 | -0.24 | -9.1% | 11.80 | +2.5% | +0.0% | +4.2% | -2.5% | -0.8% | -7.6% | +11.9% | — |
| Aug 8, 2024 | AMC | -0.23 | -0.21 | +8.7% | 13.40 | +0.7% | -0.7% | -0.7% | -0.7% | -3.0% | +0.7% | +4.5% | — |
| May 9, 2024 | AMC | -0.27 | -0.25 | +7.4% | 12.40 | +0.0% | +2.4% | +0.8% | +3.2% | +4.8% | +0.8% | -0.8% | — |
| Feb 22, 2024 | AMC | -0.51 | -0.48 | +5.9% | 12.20 | -0.8% | +0.0% | +4.9% | +13.9% | +14.8% | +20.5% | +6.6% | — |
| Nov 14, 2023 | AMC | -0.55 | -0.51 | +7.3% | 9.90 | +2.0% | +1.0% | +4.0% | +7.1% | +12.1% | +7.6% | +47.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | D. Boral Capital | Downgrade | Buy → Hold | — | $11.80 | $10.80 | -8.5% | -5.9% | -15.3% | -15.3% | -19.1% | -23.6% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.20 | $9.90 | -2.9% | +3.9% | +4.9% | +14.7% | +8.8% | +20.6% |
| Feb 13 | D. Boral Capital | Maintains | Buy → Buy | — | $8.70 | $11.30 | +29.9% | +4.9% | +5.4% | +0.8% | +12.1% | +8.0% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.20 | $6.30 | +1.6% | +15.2% | +28.2% | +19.7% | +40.3% | +47.3% |
| Jan 7 | D. Boral Capital | Maintains | Buy → Buy | — | $6.24 | $6.44 | +3.2% | +10.6% | +6.2% | +6.6% | +6.1% | +8.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.13 | $7.10 | -0.4% | +9.3% | +2.4% | +6.6% | +0.0% | -3.5% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $7.60 | $7.80 | +2.6% | -6.2% | +2.5% | -3.9% | +0.0% | -6.2% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.98 | $9.10 | +1.3% | +4.6% | +4.1% | -1.8% | +6.9% | +7.2% |
| Sep 25 | D. Boral Capital | Maintains | Buy → Buy | — | $8.79 | $8.70 | -1.0% | +2.2% | +6.8% | +6.4% | +0.3% | +9.2% |
| Aug 8 | D. Boral Capital | Maintains | Buy → Buy | — | $9.02 | $9.30 | +3.1% | -3.3% | -5.9% | -5.5% | -8.1% | +1.6% |
Recent Filings
8-K · 5.02
!!! Very High
Immunic, Inc. -- 8-K 5.02: Executive Change
Immunic appointed Michael A. Panzara as Chief Medical Officer and director effective April 24, 2026, strengthening its medical leadership while simultaneously resigning from a prior directorship role.
Apr 28
8-K · 8.01
!! High
Immunic, Inc. -- 8-K 8.01: Material Event / Announcement
Immunic implemented a reverse stock split effective April 23, 2026, which consolidates shares to potentially improve stock price perception, though it does not change underlying company value or alter shareholder ownership percentages.
Apr 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
IMUX's 1-for-10 reverse stock split, effective April 27, 2026, consolidates shares to improve stock price perception and maintain exchange listing compliance, though it doesn't change fundamental value and typically signals financial distress.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
IMUX's retention bonus structure suggests leadership instability or transition risk, potentially signaling management uncertainty that could pressure the stock pending clarity on strategic direction.
Apr 10
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
IMUX regained Nasdaq compliance after falling below minimum bid price, eliminating imminent delisting risk and restoring institutional investment eligibility, supporting near-term stock stability.
Apr 1
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Multiple executive departures at IMUX and MLYS effective March 27, 2026, signal potential leadership instability that could disrupt strategic execution and warrant caution on both stocks.
Mar 31
8-K
Immunic, Inc. -- 8-K Filing
Immunic reported 2025 year-end financial results and corporate updates for its late-stage oral therapy programs targeting neurologic and gastrointestinal diseases, signaling progress in its clinical pipeline.
Feb 26
8-K · 1.01
! Medium
Immunic, Inc. -- 8-K 1.01: Equity Issuance
Immunic secured a $200 million equity issuance agreement, potentially strengthening its cash position for pipeline development and operations.
Feb 13
Data updated apr 25, 2026 3:24pm
· Source: massive.com